SAN FRANCISCO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- On February 17, 2026, Kyndryl Holdings, Inc. (NYSE: KD) filed two amended quarterly reports and one amended annual report providing further detail about problems previously reported on February 9, 2026. The recent filings reveal that “the Company’s disclosure controls and procedures and internal control over financial reporting were ineffective” as of March 31, June 30, and September 30, 2025. Each specified that “senior finance executives failed to set an ap ...

SAN FRANCISCO, Feb. 16, 2026 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against Kyndryl Holdings, Inc. (NYSE: KD) and seeks to represent investors who purchased or otherwise acquired Kyndryl securities between August 7, 2024 and February 9, 2026. The lawsuit follows the sharp selloff in Kyndryl shares (-$12.90, -55%) on February 9, 2026, after the company announced that it would not timely file its quarterly report for the quarter ended December 31, 2025, material internal control ...

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. and certain officers for alleged violations of federal securities laws during the Class Period from August 8, 2024, to August 14, 2025, seeking damages for affected investors [1][2]. Company Overview - Nutex Health Inc. is a physician-led healthcare services company that operates through three divisions: a hospital division with 24 facilities across 11 states, a population health management division, and real estate [4]. - The company primarily operates as an out-of-network provider, generating over 90% of its net patient service revenue from third-party payors, including commercial insurance and workers' compensation [4]. Legislative Context - The No Surprises Act (NSA), effective January 1, 2022, was enacted to prevent surprise out-of-network billing, requiring private health plans to cover out-of-network claims at in-network cost-sharing rates [6]. - The NSA established an independent dispute resolution (IDR) process for determining out-of-network payment amounts when negotiations fail [7]. Financial Impact - Following the implementation of the NSA, Nutex's average payment from insurers for emergency services declined by approximately 30%, with a 37% reduction for physician services reported in March 2023 [8]. - In 2024, Nutex's total revenue increased by $232.3 million to $479.9 million, with the arbitration process contributing approximately $169.7 million to this revenue increase [9]. Internal Control Issues - Nutex has acknowledged material weaknesses in its internal controls over financial reporting, including ineffective design and implementation of controls related to financial processes [9]. - The company has stated it is in the process of remediating these weaknesses [9]. Allegations and Lawsuits - The lawsuit alleges that Nutex made materially false and misleading statements regarding its business operations and financial prospects, including claims about the sustainability of revenues from its engagement with HaloMD in the IDR process [9]. - Blue Orca Capital's report accused HaloMD of engaging in fraudulent schemes to inflate payments from insurance companies, which could impact Nutex's financial stability [10][11]. Stock Price Reaction - Following the publication of the Blue Orca Report, Nutex's stock price fell by $11.18 per share (10.05%) on July 22, 2025, and further declined by $18.22 per share (16.39%) after the company announced a delay in filing its Form 10-Q on August 15, 2025 [11][13]. Recent Developments - On August 21, 2025, Nutex filed a Current Report with the SEC indicating that certain financial statements would need to be restated due to improper treatment of non-cash obligations [14].

Core Viewpoint - Maravai LifeSciences Holdings, Inc. is facing a class action lawsuit due to alleged breaches of fiduciary duties by its board of directors, following significant issues related to revenue recognition and internal controls [1][3]. Group 1: Financial Reporting Issues - On February 25, 2025, Maravai announced a postponement of its fiscal 2024 earnings release and the filing of its annual report on Form 10-K due to an error in revenue recognition, which resulted in approximately $3.9 million being incorrectly recorded [2]. - The company identified a material weakness in its internal controls over revenue recognition, necessitating additional time to assess a potential non-cash impairment charge related to goodwill from its acquisition of Alphazyme LLC [2]. - Following this announcement, Maravai's share price dropped by $0.87, or 21.70%, closing at $3.14 per share on February 25, 2025, amid unusually heavy trading volume [2]. Group 2: Allegations in Class Action Complaint - The class action complaint alleges that Maravai's executives made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [3]. - Specific allegations include the lack of adequate internal controls over financial reporting, inaccurate revenue recognition during fiscal 2024, and overstated goodwill [3]. - The complaint asserts that the positive statements made by the defendants regarding the company's business were materially misleading and lacked a reasonable basis due to these issues [3].